SIGA Technologies Inc logo

SIGA Technologies Inc(SIGA)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.4
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for SIGA

11/20/2026: SIGA (1-star) is currently NOT-A-BUY. Pass it for now.

SIGA Technologies is a commercial-stage pharmaceutical company specializing in health security and biodefense countermeasures, anchored by its flagship smallpox antiviral, TPOXX. The company's primary strength lies in its sole-provider status for vital national stockpile contracts backed by strong federal partnerships, historically delivering high operating margins during delivery phases. Its main growth opportunity centers on international market expansion and label expansions for broader orthopoxvirus treatments. However, investors face key risks including severe customer concentration, lumpy episodic revenue recognition, and reliance on a single core product asset. This stock is best suited for risk-tolerant or momentum-focused investors who can tolerate volatile quarterly earnings driven by unpredictable government procurement timelines.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitGrowth is intermittent and tightly bound to episodic government procurement cycles rather than steady commercial expansion.
Momentum investorStrong fit while signal remains positiveThe stock frequently experiences sharp price spikes driven by headlines related to public health emergencies or major government contract awards.
Value investorMixed fitValuations can fluctuate drastically based on lumpy revenue recognition, making traditional valuation models challenging to apply consistently.
Dividend investorWeak fitDividend payouts are irregular and dependent on lumpy cash inflows from periodic government contracts rather than steady yields.
Low-risk investorWeak fitHigh customer concentration and high stock price volatility relative to news flow create meaningful headline and execution risks.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock reacts sharply to public health news, government funding updates, and contract delivery timelines.
Valuation riskMedium / highEarnings unpredictability makes forward-looking valuation multiples subject to sudden shifts.
Competition risk (government contract and biodefense competition)MediumAlternative countermeasures or shifting government priorities could impact future sole-source awards.
Business qualityMedium / highThe company maintains high operating margins during delivery phases backed by strong sovereign partnerships.
Dividend incomeLowThe company is not positioned as a reliable income vehicle for dividend-focused investors.
Execution riskMediumSuccessful clinical trials and regulatory approvals for expanded indications are necessary for long-term pipeline growth.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 172.45M USD
Price to earnings Ratio 240
1Y Target Price 3.25
Price to earnings Ratio 240
1Y Target Price 3.25
Volume (30-day avg) 547.8K shares
Beta 1.04
52 Weeks Range 2.30 - 6.29
Updated Date 11/21/2026
52 Weeks Range 2.30 - 6.29
Updated Date 11/21/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.01

Sector & Industry Intelligence

Sector

Healthcare

Constructive
Sentiment
Strong Bullish
Momentum
BUY Breadth Improving
BUY participation
55.2%
Active BUY / eligible
53 / 96
30-Day BUY Count Change
+19
Market state
Strong Bullish

More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
75.0%
Active BUY / eligible
9 / 12
30-Day BUY Count Change
+4

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -13.55%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
SIGA receives a 4-star rating, supported by strong unit economics, solid company fundamentals, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
SIGA has solid overall fundamentals (4 stars), with solid financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, strong cash generation (FCF margin 45.6%) and strong profitability (net margin 24.6%) are partially offset by negative earnings growth (-60.7%), negative revenue growth (-31.8%).

Financial Health Rating

★★★★★
SIGA's financial health is supported by strong liquidity, including working-capital and asset support (WC/assets 88.8%). Operating efficiency is solid (4 stars), which helps explain the 4-star overall score.

Growth Momentum Score

★★★★★
SIGA's growth profile is soft, with the least-weak measure being free-cash-flow growth at -11.5% FY2025 versus FY2024. By comparison, while revenue growth (-31.8%, negative) and earnings growth (-60.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 47.7% and approximately 57.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 42.73% supports management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 5.83%
AltraVue Capital, LLC 3.24%
Dimensional Fund Advisors, Inc. 2.80%
Vanguard Capital Management, LLC 2.38%
Arrowstreet Capital Limited Partnership 2.05%

Unit Economics (Per $1K Revenue)

★★★★★
SIGA generates approximately $686 of gross profit, $251 of operating income, and $456 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Strong margins, cash conversion, and capital efficiency support the rating.

Economic Dimensions

★★★★★
Effective Tax Rate: 23.36%

Quantitative Style Profile

★★★★★
SIGA has a liquid profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
US Government ContractsProcurement sales of TPOXX (oral and IV formulations) to the US Strategic National Stockpile and funding support from BARDA.The vast majority of revenue comes from supplying government stockpiles to protect against smallpox and related threats.
International and Other SalesSales of TPOXX to foreign governments and international public health agencies seeking biodefense stockpiles.International procurement provides secondary revenue diversification outside of the core US market.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE 240
Forward PE 2.51
Enterprise Value 75.03M
Price to Sales(TTM) 3.29
Enterprise Value 75.03M
Price to Sales(TTM) 3.29
Enterprise Value to Revenue 1.43
Enterprise Value to EBITDA 3.71
Shares Outstanding 71.86M
Shares Floating 41.12M
Shares Outstanding 71.86M
Shares Floating 41.12M
Percent Insiders 42.73
Percent Institutions 47.69

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.